Compare LSTA & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSTA | NSRX |
|---|---|---|
| Founded | 1980 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 36.9M |
| IPO Year | 2000 | N/A |
| Metric | LSTA | NSRX |
|---|---|---|
| Price | $3.36 | $3.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $15.00 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 95.2K | 43.5K |
| Earning Date | 05-11-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $1.81 | $1.98 |
| 52 Week High | $5.07 | $9.99 |
| Indicator | LSTA | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 55.11 |
| Support Level | $3.06 | $2.78 |
| Resistance Level | $3.41 | $3.58 |
| Average True Range (ATR) | 0.13 | 0.26 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 2.86 | 81.67 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.